Acambis warns of delay in US contract
Tuesday 26 November 2002
Acambis, the biotech group whose fortunes were transformed by orders for a smallpox vaccine, admitted yesterday that it has suffered delays to its flagship contract to supply the US government.
The disappointment overshadowed news that the company has signed two more contracts with countries concerned about the threat of a bioterrorist attack.
Some £25m of revenue that had been expected to come through before Christmas will now be delayed into next year, after Acambis found itself unable to carry out the necessary testing on batches of the smallpox vaccine, which is made from cowpox.
John Brown, the chief executive, said: "We had a shortage of a chemical agent used in the testing, so we had the product backed up waiting to be tested. The revenue of $428m [£273m] from the contract is staying the same, the margins are staying the same, but some of the money that we said would come in during the fourth quarter of this year will now come in during the first quarter of next year."
The news sent Acambis shares down more than 10 per cent in early trading, but they recovered to close off only 4 per cent at 250.5p as analysts maintained their bullish stance. Nomura had been forecasting a maiden profit of £8.1m for 2002, and while that has now been reduced to £1.6m, the 2003 profit figure has grown from £27.7m to £36.1m.
Mr Brown refused to identify the two countries who have signed contracts for the supply of smallpox vaccine, but said they would be "small in comparison" with the US deal. Analysts expect revenues will be in "single-figure millions" of dollars.
A third country, Austria, has signalled its intention to buy smallpox vaccine from Acambis, but it is yet to sign a deal.
The US had a small supply deal with Acambis which it expanded after 11 September last year as fears grew that terrorists could use smallpox as a biological weapon. It is now buying 209 million doses, enough to inoculate every citizen.
- 1 Autistic adults could take pure MDMA to 'reduce social anxiety'
- 2 Before you complain about your GP, this is what you need to know about actually doing the job
- 3 Father of 12 accused of raping, beating, starving and abusing his own children in US 'cult'
- 4 Britain's Got Talent 2015: Jamie Raven divides Twitter as fans expose mind-boggling magic trick
- 5 Charlie Charlie Challenge explained: not a Mexican demon being summoned — it's gravity
People are criticising Fifa World Cup sponsors with corrupt corporate logos
Natalie Portman tells Harvard graduates: 'Accept your lack of knowledge'
British tourists complain impoverished boat migrants are making holidays 'awkward' in Kos
Fifa corruption live: Sebb Blatter warns 'more bad news may follow' as he clings to power
Skull found in Spain could be the world's first-ever murder victim
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Australian man punched in the face for defending Muslim women from abuse on train
A nation of inequality: How the UK is failing to feed its most vulnerable people
David Starkey 'tells Amal Clooney to shut up and stop over-promoting human rights'
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...